ObsEva SA (NASDAQ:OBSV) has been given a $25.00 price objective by HC Wainwright in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 133.43% from the stock’s previous close.

A number of other research analysts also recently issued reports on OBSV. Zacks Investment Research raised ObsEva SA from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 price target on shares of ObsEva SA in a report on Wednesday, August 16th. Royal Bank Of Canada started coverage on ObsEva SA in a report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Credit Suisse Group started coverage on ObsEva SA in a report on Monday, October 9th. They set an “outperform” rating and a $16.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $18.83.

Shares of ObsEva SA (NASDAQ:OBSV) opened at 10.71 on Monday. ObsEva SA has a 52-week low of $5.00 and a 52-week high of $14.69. The company has a 50-day moving average price of $8.74 and a 200-day moving average price of $7.80. The stock’s market capitalization is $305.19 million.

ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.13). During the same quarter in the previous year, the company earned ($0.30) earnings per share. On average, equities analysts anticipate that ObsEva SA will post ($2.46) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Analysts Give ObsEva SA (OBSV) a $25.00 Price Target” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/30/hc-wainwright-reiterates-buy-rating-for-obseva-sa-obsv.html.

A number of institutional investors have recently bought and sold shares of OBSV. Paloma Partners Management Co purchased a new stake in ObsEva SA during the first quarter valued at $131,000. Sphera Funds Management LTD. increased its position in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after acquiring an additional 20,411 shares during the last quarter. VHCP Management II LLC purchased a new stake in ObsEva SA during the second quarter valued at $1,283,000. Finally, Sectoral Asset Management Inc increased its position in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after acquiring an additional 137,331 shares during the last quarter. Institutional investors own 48.46% of the company’s stock.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.